Background: Hepatic expression of microRNA-107 is ubiquitously upregulated in various
metabolic diseases. In our previous study, we had demonstrated that fatty acid synthase …

AIM: To assess the regulatory effect of microRNA-185 (miR-185) on lipid metabolism and the
insulin signalling pathway in human HepG2 hepatocytes and a high-fat diet mouse model …

Non-alcoholic fatty liver disease (NAFLD) affects obesity-associated metabolic syndrome,
which exhibits hepatic steatosis, insulin insensitivity and glucose intolerance. Previous …

The prevalence of Non-alcoholic fatty liver diseases (NAFLD) increased rapidly in the world.
However, the pathogenesis of is still unclear. Hepatic steatosis and insulin resistance are …

Backgrounds The incidence of nonalcoholic fatty liver disease (NAFLD) is rapidly increasing
due to the prevalence of obesity. NAFLD is a major risk factor of hepatocellular carcinoma …

Emerging evidence suggests that microRNAs (miRNAs) are essential for metabolic
haemostasis of liver tissues. Among them, miR‐33a is supposed to modulate the cholesterol …

Non‑alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases
worldwide. Increasing evidence has shown that microRNAs (miRNAs) play a vital role in the …

Abstract Background & Aims Insulin resistance is strongly associated with non‐alcoholic
fatty liver disease, a chronic, obesity–related liver disease. Increased endoplasmic reticulum …

Nonalcoholic fatty liver disease (NAFLD) is a metabolic‐related disorder ranging from
steatosis to steatohepatitis, which may progress to cirrhosis and hepatocellular carcinoma …

Hepatic steatosis is a global epidemic that is thought to contribute to the pathogenesis of
type 2 diabetes. MicroRNAs (miRs) are regulators that can functionally integrate a range of …